Have a feature idea you'd love to see implemented?
Let us know!
KZR Kezar Life Sciences Inc
Price (delayed)
$0.8018
Market cap
$58.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.36
Enterprise value
$47.84M
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule
Highlights
The debt has contracted by 13% YoY and by 3.7% from the previous quarter
The net income has contracted by 19% YoY but it has grown by 2.7% from the previous quarter
The EPS has declined by 18% year-on-year but it is up by 2.9% since the previous quarter
The quick ratio fell by 46% YoY and by 16% QoQ
KZR's equity is down by 35% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of KZR
Market
Valuations
Earnings
Shares outstanding
72.96M
Market cap
$58.5M
Enterprise value
$47.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
Revenue
$7M
EBIT
-$96.97M
EBITDA
-$95.89M
Free cash flow
-$79.21M
Per share
Balance sheet
Liquidity
EPS
-$1.36
Free cash flow per share
-$1.09
Book value per share
$2.07
Revenue per share
$0.1
TBVPS
$2.47
Total assets
$179.92M
Total liabilities
$29.24M
Debt
$17.61M
Equity
$150.69M
Working capital
$150.12M
Debt to equity
0.12
Current ratio
9.58
Quick ratio
9.38
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
-1,369.9%
Gross margin
100%
Net margin
-1,408.1%
Operating margin
-1,531.6%
Return on assets
-46.4%
Return on equity
-54.5%
Return on invested capital
-52.9%
Return on capital employed
-59.7%
Return on sales
-1,385.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KZR stock price
How has the Kezar Life Sciences stock price performed over time
Intraday
-0.15%
1 week
-1.74%
1 month
45.25%
1 year
-8.7%
YTD
-15.37%
QTD
3.7%
Financial performance
How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$7M
Gross profit
$7M
Operating income
-$107.21M
Net income
-$98.57M
Gross margin
100%
Net margin
-1,408.1%
The net income has contracted by 19% YoY but it has grown by 2.7% from the previous quarter
The company's operating income fell by 19% YoY but it rose by 3.1% QoQ
The operating margin has grown by 3.1% from the previous quarter
The net margin has grown by 2.7% from the previous quarter
Growth
What is Kezar Life Sciences's growth rate over time
Valuation
What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.39
P/S
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
The EPS has declined by 18% year-on-year but it is up by 2.9% since the previous quarter
The price to book (P/B) is 76% less than the 5-year quarterly average of 1.6 and 2.5% less than the last 4 quarters average of 0.4
KZR's equity is down by 35% year-on-year and by 11% since the previous quarter
The price to sales (P/S) is 12% lower than the last 4 quarters average of 9.5
Efficiency
How efficient is Kezar Life Sciences business performance
KZR's ROE has shrunk by 71% YoY and by 8% QoQ
The company's return on invested capital has shrunk by 65% YoY and by 9% QoQ
The return on assets has dropped by 62% year-on-year and by 7% since the previous quarter
The return on sales is up by 2.8% since the previous quarter
Dividends
What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KZR.
Financial health
How did Kezar Life Sciences financials performed over time
KZR's current ratio is down by 46% year-on-year and by 17% since the previous quarter
The quick ratio fell by 46% YoY and by 16% QoQ
The debt is 88% less than the equity
KZR's equity is down by 35% year-on-year and by 11% since the previous quarter
KZR's debt to equity is up by 33% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.